Nordicus Partners is a US-listed biotech holding company that operates as a venture accelerator for early-stage life science companies in the Nordic region. Nordicus identifies and acquires companies developing preclinical drug candidates, specifically targeting oral disorders and inflammatory diseases with significant unmet medical needs. Nordicus maintains a portfolio of three subsidiaries: Orocidin, Bio-Convert, and NoviThera. Orocidin is developing QR-01, a topical treatment for aggressive periodontitis, with Phase IIa trials planned for H1 2027. Bio-Convert is developing QR-02, an oral gel for oral leukoplakia, a pre-cancerous condition with no currently approved medical treatment, and expects Phase IIa entry in H1 2027. NoviThera is developing QR-04, a monoclonal antibody for psoriasis. Nordicus does not conduct internal drug discovery. Instead, the company provides capital and operational support to advance programs through preclinical and early clinical development. Nordicus typically acquires assets using its own stock and intends to exit investments through sales, partnerships with large pharmaceutical companies, or initial public offerings once candidates reach Phase I or Phase IIa completion. While Nordicus is incorporated in the US, its scientific operations are based in Denmark to utilize the Scandinavian life science ecosystem. Nordicus is a pre-revenue enterprise funded by equity issuances.